Evidence map›Paper›PMID 32132233›Full record

ArticleJournal of virology2020

T Cell Responses Induced by Attenuated Flavivirus Vaccination Are Specific and Show Limited Cross-Reactivity with Other Flavivirus Species.

Alba Grifoni, Hannah Voic, Sandeep Kumar Dhanda, Conner K Kidd, James D Brien, Søren Buus, Anette Stryhn, Anna P Durbin, Stephen Whitehead, Sean A Diehl and 5 more

Abstract read
In one paragraph

Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Dengue Dilemma: Navigating Cross-Reactivity and Immune Challenges.Current topics in microbiology and immunology · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Human T Cell Responses to Flavivirus Vaccines.European journal of immunology · 2025
    Review
  11. Review
  12. Article
  13. Article
  14. The characterization of CD8Emerging microbes & infections · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Alba GrifoniDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, California, USA.
Hannah VoicDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, California, USA.
Sandeep Kumar DhandaDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, California, USA.
Conner K KiddDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, California, USA.
James D BrienSaint Louis University, Saint Louis, Missouri, USA.
Søren BuusLaboratory of Experimental Immunology, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Anette StryhnLaboratory of Experimental Immunology, Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Anna P DurbinJohns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
Stephen WhiteheadNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Sean A DiehlUniversity of Vermont School of Medicine, Burlington, Vermont, USA.
Aruna D De SilvaDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, California, USA.
Angel BalmasedaNational Virology Laboratory, National Center for Diagnosis and Reference, Ministry of Health, Managua, Nicaragua.
Eva HarrisDivision of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, California, USA.
Daniela WeiskopfDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, California, USA.
Alessandro SetteDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, California, USA alex@lji.org.

Funding

Clinical Trials of Biodefense Vaccines (Dengue, West Nile Virus, TBEV)ZIAAI000987 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI WHITEHEAD, STEPHEN · 2009 to 2025
$37.9M
T Cell Responses Following DENV Natural Infections and Live-Attenuated Dengue Virus VaccinationP01AI106695 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI Aravinda M. DeSilva · 2015 to 2026
$34.1M
NIAID NIH HHS HHSN272200900010CNIAID NIH HHS HHSN272200900042CNIAID NIH HHS HHSN272200900045CNIAID NIH HHS HHSN272201400045CNIAID NIH HHS P01 AI106695
6 · The paper itself

Abstract

Members of the flavivirus genus share a high level of sequence similarity and often circulate in the same geographical regions. However, whether T cells induced by one viral species cross-react with other related flaviviruses has not been globally addressed. In this study, we tested pools of epitopes derived from dengue (DENV), Zika (ZIKV), Japanese encephalitis (JEV), West Nile (WNV), and yellow fever (YFV) viruses by intracellular cytokine staining (ICS) using peripheral blood mononuclear cells (PBMCs) of individuals naturally exposed to DENV or immunized with DENV (TV005) or YF17D vaccine. CD8 T cell responses recognized epitopes from multiple flaviviruses; however, the magnitude of cross-reactive responses was consistently severalfold lower than those to the autologous epitope pools and was associated with lower expression of activation markers such as CD40L, CD69, and CD137. Next, we characterized the antigen sensitivity of short-term T cell lines (TCL) representing 29 different individual epitope/donor combinations. TCL derived from DENV monovalent vaccinees induced CD8 and CD4 T cells that cross-reacted within the DENV serocomplex but were consistently associated with >100-fold-lower antigen sensitivity for most other flaviviruses, with no cross-recognition of YFV-derived peptides. CD8 and CD4 TCL from YF17D vaccinees were associated with very limited cross-reactivity with any other flaviviruses and in five out of eight cases >1,000-fold-lower antigen sensitivity. Overall, our data suggest limited cross-reactivity for both CD4 and CD8 T cell responses between flaviviruses and have implications for understanding immunity elicited by natural infection and strategies to develop live attenuated vaccines against flaviviral species.

Indexed as

VaccinationAdolescentAdultAntibodies, NeutralizingAntibodies, ViralCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCross ReactionsDengueDengue VaccinesDengue VirusEncephalitis, JapaneseEpitopes, T-LymphocyteFemaleFlavivirusFlavivirus InfectionsAntibodies, NeutralizingAntibodies, ViralDengue VaccinesEpitopes, T-LymphocyteVaccines, AttenuatedViral VaccinesYellow Fever VaccineDENVflavivirusesT cellsvaccinesYFV

Identifiers

PMID32132233
PMCPMC7199411

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.